EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 183 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 1.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $337,320 | -61.1% | 21,390 | -52.0% | 0.00% | – |
Q2 2023 | $866,091 | -27.3% | 44,552 | +6.1% | 0.00% | -100.0% |
Q1 2023 | $1,191,455 | -6.4% | 41,997 | -3.5% | 0.00% | 0.0% |
Q4 2022 | $1,272,499 | +21.8% | 43,534 | +10.1% | 0.00% | 0.0% |
Q3 2022 | $1,045,000 | -41.0% | 39,556 | -0.8% | 0.00% | 0.0% |
Q2 2022 | $1,771,000 | -10.4% | 39,860 | -0.2% | 0.00% | 0.0% |
Q1 2022 | $1,977,000 | -4.7% | 39,949 | -1.9% | 0.00% | 0.0% |
Q4 2021 | $2,074,000 | -8.7% | 40,733 | +0.0% | 0.00% | 0.0% |
Q3 2021 | $2,271,000 | +25.5% | 40,722 | -3.7% | 0.00% | 0.0% |
Q2 2021 | $1,810,000 | +23.5% | 42,279 | +20.4% | 0.00% | 0.0% |
Q1 2021 | $1,466,000 | +10.3% | 35,122 | +23.1% | 0.00% | 0.0% |
Q4 2020 | $1,329,000 | +3.5% | 28,532 | -5.6% | 0.00% | 0.0% |
Q3 2020 | $1,284,000 | -23.5% | 30,232 | -13.6% | 0.00% | 0.0% |
Q2 2020 | $1,679,000 | +4.2% | 34,990 | -0.1% | 0.00% | 0.0% |
Q1 2020 | $1,612,000 | -24.7% | 35,040 | -1.7% | 0.00% | 0.0% |
Q4 2019 | $2,141,000 | +6.5% | 35,640 | +0.3% | 0.00% | 0.0% |
Q3 2019 | $2,010,000 | -4.8% | 35,540 | -6.3% | 0.00% | 0.0% |
Q2 2019 | $2,112,000 | +12.9% | 37,940 | +2.4% | 0.00% | 0.0% |
Q1 2019 | $1,871,000 | +12.8% | 37,060 | -10.0% | 0.00% | 0.0% |
Q4 2018 | $1,658,000 | -45.4% | 41,160 | -6.1% | 0.00% | -50.0% |
Q3 2018 | $3,038,000 | -8.3% | 43,820 | +0.0% | 0.00% | 0.0% |
Q2 2018 | $3,314,000 | +247.0% | 43,800 | +141.7% | 0.00% | +100.0% |
Q1 2018 | $955,000 | -44.3% | 18,118 | -43.6% | 0.00% | 0.0% |
Q4 2017 | $1,715,000 | +0.9% | 32,110 | +12.6% | 0.00% | 0.0% |
Q3 2017 | $1,700,000 | -27.6% | 28,510 | -4.2% | 0.00% | -50.0% |
Q2 2017 | $2,349,000 | +95.3% | 29,770 | +105.3% | 0.00% | +100.0% |
Q1 2017 | $1,203,000 | -2.8% | 14,500 | -7.1% | 0.00% | 0.0% |
Q4 2016 | $1,238,000 | +13.4% | 15,600 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $1,092,000 | +80.5% | 15,600 | 0.0% | 0.00% | 0.0% |
Q2 2016 | $605,000 | -4.3% | 15,600 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $632,000 | -53.4% | 15,600 | +2.0% | 0.00% | 0.0% |
Q4 2015 | $1,357,000 | +17.0% | 15,300 | -2.4% | 0.00% | 0.0% |
Q3 2015 | $1,160,000 | -8.7% | 15,670 | -0.2% | 0.00% | 0.0% |
Q2 2015 | $1,270,000 | – | 15,700 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JW Asset Management, LLC | 475,755 | $25,068,000 | 24.71% |
Hudson Executive Capital LP | 971,000 | $51,162,000 | 15.09% |
Park West Asset Management LLC | 1,051,274 | $55,392,000 | 2.47% |
U S GLOBAL INVESTORS INC | 19,200 | $1,012,000 | 0.62% |
Capital Impact Advisors, LLC | 26,317 | $1,387,000 | 0.57% |
CLARK ESTATES INC/NY | 56,278 | $2,965,000 | 0.47% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 873,131 | $46,005,000 | 0.41% |
ProQuest Associates IV LLC | 6,777 | $357,000 | 0.41% |
Granite Investment Partners, LLC | 114,207 | $6,017,000 | 0.40% |
GLOBEFLEX CAPITAL L P | 30,900 | $1,628,000 | 0.34% |